Development of hypocomplementemic urticarial vasculitis during certolizumab pegol treatment for rheumatoid arthritis: A case report.
Antirheumatic Agents
/ administration & dosage
Arthritis, Rheumatoid
/ drug therapy
Certolizumab Pegol
/ administration & dosage
Female
Hereditary Complement Deficiency Diseases
/ chemically induced
Humans
Middle Aged
Prednisolone
/ administration & dosage
Urticaria
/ chemically induced
Vasculitis
/ chemically induced
certolizumab pegol
hypocomplementemic urticarial vasculitis
rheumatoid arthritis
Journal
Journal of clinical pharmacy and therapeutics
ISSN: 1365-2710
Titre abrégé: J Clin Pharm Ther
Pays: England
ID NLM: 8704308
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
13
10
2019
revised:
12
11
2019
accepted:
06
01
2020
pubmed:
29
1
2020
medline:
11
8
2021
entrez:
29
1
2020
Statut:
ppublish
Résumé
Tumour necrosis factor-α-blocking agents potentially cause vasculitis. However, no study has reported on the association between hypocomplementemic urticarial vasculitis (HUV) and certolizumab pegol (CZP) usage. We present the first case of HUV development during CZP treatment for rheumatoid arthritis. Hypocomplementemic urticarial vasculitis improved after CZP was discontinued and the dose of oral prednisolone was increased. Clinicians should be aware about the potential development of HUV during CZP treatment, which is presumed to be safe considering its unique structural characteristics that differ from those of other tumour necrosis factor-α-blocking agents.
Substances chimiques
Antirheumatic Agents
0
Prednisolone
9PHQ9Y1OLM
Certolizumab Pegol
UMD07X179E
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
1179-1182Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Fujikawa K, Kawakami A, Hayashi T, et al. Cutaneous vasculitis induced by TNF inhibitors: a report of three cases. Mod Rheumatol. 2010;20(1):86-89.
Ramos-Casals M, Brito-Zerón P, Muñoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007;86(4):242-251.
Mease PJ. Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety. Rheumatology (Oxford). 2011;50(2):261-270.
Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11.
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.
Grotz W, Baba HA, Becker JU, Baumgärtel MW. Hypocomplementemic urticarial vasculitis syndrome: an interdisciplinary challenge. Dtsch Arztebl Int. 2009;106(46):756-763.
Alomari M, Al Momani L, Khazaaleh S, Almomani S, Yaseen K, Alhaddad B. Exceptional association of hypocomplementemic urticarial vasculitis syndrome (HUVS) and symptomatic pulmonary histoplasmosis: a case-based literature review. Clin Rheumatol. 2019;38(6):1691-1697.
Guillevin L, Mouthon L. Tumor necrosis factor-alpha blockade and the risk of vasculitis. J Rheumatol. 2004;31(10):1885-1887.
Mohan N, Edwards ET, Cupps TR, et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol. 2004;31(10):1955-1958.
Woody M, Warren D, Speck L, Jackson J. Leukocytoclastic vasculitis drug reaction to certolizumab pegol. Proc (Bayl Univ Med Cent). 2017;30(2):213-214.
Cassinotti A, Ardizzone S, Porro GB. Certolizumab pegol: an evidence-based review of its place in the treatment of Crohn's disease. Core Evid. 2008;2(3):209-229.
Davis MD, Daoud MS, Kirby B, Gibson LE, Rogers RS 3rd. Clinicopathologic correlation of hypocomplementemic and normocomplementemic urticarial vasculitis. J Am Acad Dermatol. 1998;38(6 Pt 1):899-905.
Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the systemic lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686.
Katz U, Zandman-Goddard G. Drug-induced lupus: an update. Autoimmun Rev. 2010;10(1):46-50.
Verma HD, Scherl EJ, Jacob VE, Bosworth BP. Anti-nuclear antibody positivity and the use of certolizumab in inflammatory bowel disease patients who have had arthralgias or lupus-like reactions from infliximab or adalimumab. J Dig Dis. 2011;12(5):379-383.
Mudduluru BM, Shah S, Shamah S, Swaminath A. TNF-alpha antagonist induced lupus on three different agents. Postgrad Med. 2017;129(2):304-306.
Fadahunsi AW, Garcia-Rosell M, Pattanaik D. Hypocomplementemic urticarial vasculitis syndrome possibly secondary to etanercept use. J Clin Rheumatol. 2015;21(5):274-275.
Buck A, Christensen J, McCarty M. Hypocomplementemic urticarial vasculitis syndrome: a case report and literature review. J Clin Aesthet Dermatol. 2012;5(1):36-46.
Juan A, Ribas B, Nadal C, Ros I. Treating leukocytoclastic vasculitis associated with etanercept therapy. is it necessary to stop etanercept? J Rheumatol. 2005;32(10):2061.